Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

NCT04381832 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant
Androgen-Resistant Prostatic Neoplasms
Castration Resistant Prostatic Neoplasms
Prostatic Cancer, Castration-Resistant

Interventions

DRUG: Etrumadenant
DRUG: Zimberelimab
DRUG: Quemliclustat
DRUG: Enzalutamide
DRUG: Docetaxel
DRUG: SG

Sponsor

Arcus Biosciences, Inc.

Collaborators

[object Object]